Chamcromus 0.1% Tw2 ointment for eczema (10g)

Dosage form Box of 1 tube x 10g
Specifications Tacrolimus
Ingredient Central Pharmaceutical Joint Stock Company 2

Ingredient

Composition information	Content
Tacrolimus	0.1%

Uses

indicators

0.1% of the skin's skin ointment is indicated in the following cases:

attack treatment:

Short -term and interrupted treatment for eczema (organ dermatitis) from moderate to severe for people aged 16 and over.

Has treated with other non -skin drugs that cannot be cured or other skin drugs are not recommended as corticosteroid skin.

Maintain treatment:

Preventing the outbreak of eczema (such as Eczema) with high frequency (over 4 times per year) and prolonging the disease.

Pharmacokology

ATC code: D11AH01

Division of drugs: Corticosteroid anti -inflammatory drugs

tacrolimus is a macrolid immunosuppressant that is extracted from streptomyces tsukubaensis that has the same immunosuppressive effect like cyclosporin but not related to the structure. The mechanism of immunosuppressive effects of Tacrolimus is not well known.

tacrolimus has the effect of inhibiting T cells T, through inhibition of Interleukin-2 production. Tacrolimus inhibits 100 times the immunosuppressor of the same dosage.

It has shown that Tacrolimus inhibits activating T lymphocytes by cohesion to an intracellular protein, FKBP-12. Tacrolimus-FKBP-12 complex, calcium calmodulin and calcinerurin ions are formed and inhibited phosphatase activity of calcinerurin and therefore has the ability to prevent phosphorylation and transfer of T-cells factor (NF-AT) to be activated, an ingredient of cell humanity through processing.

Tacrolimus also inhibits the transcription of genes with symbols IL-3, IL-4, IL-5, GM-CSF and TNF-A, all of these genes are involved in the activity process at the initial stage T.

It is also proved that Tacrolimus has the ability to inhibit the release of intermediate substances that have been formed from skin moisturizers, alkaline leukocytes and reduce the manifestations of high -pitched receptors on Langerhans cells.

tacrolimus is used to prevent transplantation of organization in liver, kidney, and heart transplant. The drug is also used to treat Crohn disease with holes and on -site treatment of allergies.

In patients with eczema, the recovery of skin damage while treating with Tacrolimus ointment is associated with a decrease in the cohesion of FC receptors on langerhans cells and reducing their stimulating activity to Tacrolimus ointments does not affect collagen synthesis in humans.

Dynamic pharmacokinetics

Clinical data shows that the concentration of Tacrolimus during the body circulation after use is low and when measured, it only feels transient. Data from healthy people show that there is no or very little exposure to the body with Tacrolimus when taking Tacrolimus ointment on the spot alone or repeating. Most organic eczema patients are treated with solitary or repeated Tacrolimus ointment (0.03 - 0.3%) with blood concentration in blood Due to the low exposure of the body with Tacrolimus ointment, the high cohesion of Tacrolimus (> 98.8%) with plasma proteins is considered as clinically unrelated

Tacrolimus metabolism in human skin has not been found. Tacrolimus in the body is completely metabolized in the liver via CYP3A4.

With the topical ointment, the average half -life of Tacrolimus is estimated at 75 hours for adults and 65 hours for children.

Before taking Chamcromus 0.1% Tw2 ointment for eczema (10g)

How to use

Apply a thin layer of medication to the sick skin. Apply the drug twice a day, apply 1 time in the morning, apply 1 time in the evening until the Eczema starts. The disease will help in 1 week of taking the drug. If after 2 weeks of taking the drug, the disease does not have to go to the doctor again.

Dosage

Offensive treatment:

Use medicine for patients 16 years and older: Starting with thin layer of 0.1% Chamcromus ointment to the area of the disease including facial and folding skin but not applied to the mucosa, 2 times a day, must apply the minimum amount to fully control the infected skin until from skin damage. If the disease recurs, apply Chamcromus 0.1% 2 times a day. If the disease progresses well, it is advisable to reduce the number of use or use of Chamcromus ointment 0.03%.

Stop taking the drug when signs or symptoms of dermatitis have recovered after 1 week of treatment.

If the signs or symptoms of dermatitis (itching, burning, redness) do not improve after 2 weeks of treatment, patients should see a doctor again.

Apply medicine only to the sick skin according to the instructions of the physician because of the continuous and prolonged medication that causes Calcineurin inhibitors.

After applying the medication, this skin should not be bandaged.

For the elderly: do not adjust the dose.

Maintain treatment:

Used for patients responding to treatment for 6 weeks of drug treatment such as recovering, near or slightly affected skin damage.

Used for patients aged 16 and older: Applying Chamcromus 0.1% once a day, 2 times a week (for example, applying the drug on Monday and Thursdays every week) to the sick skin to prevent the disease from becoming acute. If the disease shows signs of acute recurrence, return to drug treatment as in the attack treatment. If the physician assigns treatment for more than 12 months for the patient, the condition must be reviewed.

For the elderly: do not adjust the dose.

Apply medicine only to the sick skin according to the instructions of the physician because of the continuous and prolonged medication that causes Calcineurin inhibitors.

After applying the medication, this skin should not be bandaged.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

If the overdose occurs, the patient needs to see a doctor immediately for timely treatment: evaluating signs of survival, clinical symptoms and supportive treatment.

In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Chamcromus 0.1% common effects (ADR) such as:

Common disorders and status at the position of drug use: burning, itching, irritation, irritation at the drug position.

Infections and parasites: Herpes virus infection, eye herpes, folliculitis, lip herpes, Kaposi chickenpox blister.

Disorders of skin and subcutaneous tissue:

Common: itching, on -site irritation.

Common: Perceptions and sensory disorders (increased sensitivity, burning sensation).

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

0.1% Chamcromus drug in the following cases:

hypersensitively to the macrolid group in general, with tacrolimus or any ingredients of the drug. Or macrolid antibiotics such as azithromycin, clarithromycin, erythromycin, telithromycin.

adults with immunodeficiency.

Be cautious when used

Patients with eczema organs are susceptible to skin infections. If there is a clinical skin infection, the risk and benefits of the use of 0.1%0.1%Chamcromus ointment. Has recorded rare malignant cases including malignant diseases of skin and lymphatic have been reported in patients using 0.1%Chamcromus ointment.

During the use of 0.1%Chamcromus ointment, skin exposure should be limited to natural light or artificial light.

Do not use 0.1% Chamcromus ointment in patients with damaged skin protective barriers: Netherton syndrome, Psoriasis peeled, body erythema.

If the signs and symptoms of the eczema are not improved, the next use should be considered. Avoid contacting the eye or mouth, mucosa and open skin areas.

The effect of the drug on the ability to drive and operate machinery

unknown effects of the drug.

Use drugs for women during pregnancy and nursing mothers

Be cautious when using Chamcromus ointment in pregnant women.

The whole body is used in milk, so it does not use even external skin for nursing women.

Medicinal interaction

Modable interaction may occur when using drugs on wide skin. CYP3A4 metabolic inhibitors can affect the bioavailability of the drug such as bromocriptine, dexamethasone, erythromycin, ketoconazole, miconazole, omeprazole, ...

Should avoid using the drug simultaneously with UVA, UVB treatment therapy or combined with Psoralen (Puva).

Storage

Leave a cool place, avoid light, temperatures below 30⁰C.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.